9 results about "Oil Red O" patented technology

The invention relates to the technical field of biology, in particular to application of a GGPS1 activator, a pharmaceutical composition, a kit and a method. The invention relates to bone metabolism regulation and bone regeneration. It is found that improvement of GGPS1 expression / activity can activate TGF-beta / Smad2 / 3 by down-regulating LTBP1, so that human bone marrow mesenchymal stem cells are converted from adipogenesis to osteogenesis, and bone formation and bone defect repair are promoted. The invention provides a drug containing a GGPS1 activator and a controlled release composition for implantation, which are used for osteoporosis, bone mass reduction, delayed fracture healing and the like. The invention also provides an in-vitro screening and evaluation method and a detection kit, and the indexes such as p-Smad2 / 3, alizarin red, oil red O and the like are used for judgment. The invention realizes upstream heavy balance and has the advantages of bone promotion and fat suppression.

The invention discloses a fermentation method for fungus-enzyme synergistic treatment of lucid ganoderma and application of the method in pet food. The fermentation method comprises the following steps: (1) enzymolysis pretreatment: mixing ganoderma lucidum sporocarp powder with water, adding cellulase and laccase, and performing enzymolysis to obtain an enzymolysis solution; (2) sterilizing and supplementing a carbon source: adding the carbon source into the enzymatic hydrolysate, and sterilizing; (3) lactobacillus fermentation: adding lactobacillus plantarum into the sterilized enzymatic hydrolysate, and fermenting under a fermentation condition to obtain fermentation liquor; and (4) solid-liquid separation: performing centrifugal separation on the fermentation liquor, and collecting supernate to obtain the ganoderma lucidum fermentation liquor. According to the method, the laccase and the cellulase are synergistically broken, so that the release efficiency of triterpenes and total phenols in the ganoderma lucidum with spores is remarkably improved. The fermentation liquor can improve lipid accumulation (the oil red O staining lipid content is reduced) and relieve oxidative stress injury on the cell level, and can be used for preparing functional food for improving metabolic health, especially for lipid abnormality and oxidative stress state related to metabolic dysfunction of pets.

The invention discloses application of physcion in preparation of a medicine for reducing liver cell lipid deposition, and particularly relates to application of physcion in preparation of a medicine for preventing and treating lipid deposition fatty liver. In-vitro cell experiments prove that the physcion shows low toxicity and a wide safety range in a human normal hepatocyte line THLE3, a human hepatoma cell line HepG2 and a mouse normal hepatocyte line AML12, and can obviously reduce the level of oleic acid-induced intracellular triglyceride in a dose-dependent manner, so that the physcion can be used for preparing a medicine for treating liver cancer. Oil red O staining results also visually show that lipid droplet accumulation in cells can be effectively reduced; according to the invention, the technical prejudice that the emodin monomethyl ether is regarded as a potential hepatotoxic component in the prior art is overcome, a safe and effective new choice is provided for the treatment of the lipid deposition fatty liver, and the pharmaceutical composition has a wide clinical application prospect.

This invention discloses a method for evaluating the bioavailability of soybean oil based on an in vitro digestion / cell co-culture model. Soybean oil is emulsified using WPI emulsifier and then digested sequentially through simulated gastric and intestinal fluids to obtain the gastric digestion products of soybean oil. Fatty acids are extracted from the intestinal digestion products of soybean oil, dissolved in dimethyl sulfoxide, and linked to fatty acid-free bovine serum albumin to obtain in vitro digestion products of soybean oil that can be absorbed by the intestines. These are then added to a cell co-culture model for cell incubation and transport. HepG2 cells from the cell co-culture model are collected, and Oil Red O staining and total triglyceride content are measured to obtain lipid deposition, thereby evaluating the bioavailability of soybean oil. The in vitro digestion / cell co-culture model of this invention is specifically designed for soybean oil digestion. This method objectively and scientifically evaluates the bioavailability of soybean oil at different metabolic stages, providing a standard basis for the scientific and healthy consumption of soybean oil and possessing significant practical value.

The invention discloses a dynamic detection method for mouse liver organoid response lipid, and belongs to the technical field of biological research. Culturing the liver-like organs of the mouse to a preset number of days; randomly dividing the organs into at least three groups, and respectively treating by using a complete culture medium, a culture medium containing free fatty acid and a culture medium containing cholesterol; after the treatment is finished, sequentially carrying out bright field imaging and oil red O dyeing imaging on the same batch of organ-like samples; organ-like morphological parameters obtained by bright field images and the overall accumulation condition of neutral lipid disclosed by oil red O staining images are integrated and analyzed, and the cell growth condition of mouse liver organ-like cells and histological morphological change of the organ-like are evaluated by HE staining. Therefore, multi-dimensional and visual distinguishing and quantitative evaluation of lipid metabolism response induced by fatty acid and cholesterol are realized. According to the method, form-phenotype-molecule comprehensive evaluation is realized, and the problems that in the prior art, the information dimension is limited, and different lipid responses cannot be accurately distinguished are solved.

The invention discloses an application of dehydrocorydaline or a pharmaceutically acceptable salt thereof in preparation of a product for preventing and / or treating atherosclerosis and related diseases thereof. The application is verified by animal experiments based on an ApoE- / -mouse model, and results of general aorta Oil Red O staining, aortic sinus HE / Oil Red O staining, serum inflammatory factor ELISA and the like of the inventor prove that the dehydrocorydaline has remarkable morphological improvement and inflammation regulation effects on atherosclerosis. It is found for the first time that the dehydrocorydaline can be used for preparing the medicine for preventing or treating the atherosclerosis and related cardiovascular events of the atherosclerosis, and therefore a new safe and effective multi-target treatment way is provided for comprehensive intervention of the atherosclerosis.

The application discloses a new application of mulberry polysaccharide in preparation of a medicine for treating type 2 diabetes by regulating intestinal flora, and belongs to the technical field of medicinal and edible plant polysaccharides. In the application, a type 2 diabetes rat model is constructed by using high-sugar and high-fat feed in combination with streptozotocin, biochemical index detection, liver HE staining and oil red O staining, intestinal flora 16S rRNA high-throughput sequencing, and GC-MS detection of short-chain fatty acid content are carried out, so as to confirm that the mulberry polysaccharide can regulate the intestinal flora structure of T2DM rats, improve the secretion level of short-chain fatty acids, improve insulin resistance and glycolipid metabolism disorder, enhance the antioxidant capacity of the body, and repair the pathological damage of the liver. The application clearly defines the anti-type 2 diabetes mechanism of the mulberry polysaccharide, which takes the intestinal flora-short-chain fatty acid axis as the core. The mulberry polysaccharide is a natural low-toxicity medicinal and edible active ingredient, has no side effects of chemical hypoglycemic drugs, can be prepared into various oral medicine dosage forms, and is used for the prevention and clinical treatment of type 2 diabetes, so the application prospect is wide.

The invention belongs to the technical field of biology, and particularly relates to a construction method and application of a metabolism-related fatty liver disease animal model. According to the invention, AAV-ASIC1a-shRNA virus is injected into a PVN brain region of a target animal, ASIC1a channel protein is knocked down, the weight and liver weight of the target animal are increased, the triglyceride level of serum is increased, and Hamp is used as an antigen; e staining prompts that hepatocytes are obviously swollen, cell nucleuses are deviated and even disappear, the hepatocytes have obvious inflammatory change, oil red O staining lipid is obviously increased, all the characteristics reproduce clinical and existing laboratory mouse characteristics of MAFLD, and the standards of MAFLD animal models are met.

The invention discloses a pig intramuscular adipose cells (AMSCs) and pig skeletal muscle satellite cells (PSCs) co-culture system establishment method, which comprises the steps of cell separation and identification, co-culture medium preparation, co-culture operation and effect identification, and specifically comprises the following steps: step 1, cell separation and identification, step 2, co-culture medium preparation, and step 3, co-culture operation. 4, effect identification: grease formation of AMSCs is identified through oil red O staining, muscle formation of PSCs is identified through immunofluorescence staining, and the grease formation rate and the muscle formation rate are both larger than or equal to 85%. The special culture medium can meet the nutritional requirements of two cells at the same time, and the inhibition of a single culture medium on the growth or differentiation of a certain type of cells is avoided. By synchronously inducing directional differentiation of two cells, obvious myotubular structures and lipid droplets are finally formed, and the differentiation effect is stable and repeatable. And an ideal model is provided for exploring a collaborative regulation molecular mechanism of intramuscular fat deposition and muscle growth.